PrEPVacc HIV vaccine trial shows no reduction in infections

FHS
July 23, 2024
1:01 pm

The results of the PrEPVacc HIV vaccine trial conducted in Eastern and Southern Africa, which ran between 2020 and 2024, show conclusively that neither of the two experimental vaccine regimens tested reduced HIV infections among the study population.

Emmaus gains authorisation for sickle cell treatment in Oman

In Oman, almost 3,000 individuals have sickle cell disorders. Credit: Victor Josan / Shutterstock.com. Emmaus Life Sciences has received the Oman Ministry of Health’s marketing authorisation for

July 14, 2023

Novel mRNA vaccine GLB-COV2-043 shows high efficacy against COVID-19 variants in early trials

The safety, efficacy, and immunogenicity of a mRNA-based vaccine.

December 5, 2023

Coya stretches lead drug’s development to Parkinson’s and dementia – Pharmaceutical Technology

Share this article COYA 302 is an investigational combination drug made up of a low dose interleukin 2 (IL-2) drug and a CTLA4 Ig fusion

January 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.